jcm-logo

Journal Browser

Journal Browser

Advances in Maternal Fetal Medicine

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: 20 April 2026 | Viewed by 120

Special Issue Editors


E-Mail Website
Guest Editor
Emergency Department, Poison Control Center, Hospital Papa Giovanni XXIII, 24100D Bergamo, Italy
Interests: depression; anxiety disorder; pregnancy; breastfeeding; antidepressants; anxiolytics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Gemelli Isola Hospital, Via di Ponte Quattro capi, 39, 00186 Rome, Italy
Interests: gynecology; anxiety disorder; depression; pregnancy

Special Issue Information

Dear Colleagues,

The progress of maternal fetal medicine is notable and requires the collaboration of a multidisciplinary team of specialists (obstetricians, neonatologists, toxicologists). Various maternal and fetal diseases are currently curable thanks to the development of diagnostic techniques and maternal or fetal treatment.

This special issue focuses on the diagnosis, treatment, and management of high-risk pregnancies as well as the treatment of fetal pathologies. Moreover, the information published regarding the safety of the drugs administration during pregnancy offers exceptional care for many complications during pregnancy, infectious diseases, poor neonatal adaptation due to maternal drug therapy or substances abuse.

In this Special Issue, we welcome authors to submit papers on the clinical advance of maternal fetal medicine in terms of both diagnosis and treatment.

Dr. Georgios Eleftheriou
Dr. Anna Franca Cavaliere
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drugs use during pregnancy
  • fetal treatment
  • pregnancy complications
  • infectious diseases
  • neonatal poor adaptation syndrome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

20 pages, 453 KB  
Systematic Review
The Role of microRNA-210 in the Pathogenesis and Diagnosis of Preeclampsia—A Systematic Review
by Oana Eliza Cretu, Alina Alexandra Dirlau, Adrian Valeriu Neacsu, Adina Elena Nenciu and Iuliana Ceausu
J. Clin. Med. 2025, 14(21), 7593; https://doi.org/10.3390/jcm14217593 (registering DOI) - 26 Oct 2025
Abstract
Background: Preeclampsia is a complex hypertensive disorder of pregnancy associated with significant maternal and foetal morbidity and mortality. Its pathogenesis involves placental hypoxia, oxidative stress, and impaired trophoblast invasion. Recent evidence highlights the role of microRNAs, particularly microRNA-210 (miR-210), in the molecular [...] Read more.
Background: Preeclampsia is a complex hypertensive disorder of pregnancy associated with significant maternal and foetal morbidity and mortality. Its pathogenesis involves placental hypoxia, oxidative stress, and impaired trophoblast invasion. Recent evidence highlights the role of microRNAs, particularly microRNA-210 (miR-210), in the molecular disruptions underlying preeclampsia. Aim: This study aims to explore the pathogenic, diagnostic, and therapeutic significance of miR-210 in preeclampsia, with emphasis on its molecular mechanisms, biomarker potential, and prospects as a therapeutic target. Methods: A systematic narrative review was conducted following PRISMA guidelines. A total of 498,184 articles were identified through eight scientific databases, and, after duplicate removal and eligibility screening, 111 peer-reviewed studies published between 2015 and 2025 were included in the final analysis. The selected literature focused on miR-210’s expression in placental tissue and maternal circulation, its molecular targets, and its clinical relevance. Results: miR-210 is consistently upregulated in preeclamptic placentas and maternal plasma. It contributes to shallow trophoblast invasion, impaired angiogenesis, mitochondrial dysfunction, and the activation of a hypoxia-induced HIF-1α feedback loop. These mechanisms are central to the disease’s pathophysiology. Clinically, miR-210 demonstrates high stability in circulation and early detectability, making it a promising diagnostic and prognostic biomarker. Experimental models have also demonstrated the therapeutic potential of miR-210 inhibition using antisense oligonucleotides or HIF-1α modulators. Conclusions: miR-210 is both a marker and mediator of preeclampsia. Its integration into diagnostic protocols and therapeutic strategies, alongside clinical validation and standardisation, may enhance early detection and personalised care in high-risk pregnancies. Full article
(This article belongs to the Special Issue Advances in Maternal Fetal Medicine)
Show Figures

Figure 1

Back to TopTop